Ruxolitinib: a potent and selective Janus kinase 1 and 2 inhibitor in patients with myelofibrosis. An update for clinicians-Reference-Cited by-同舟云学术

Ruxolitinib: a potent and selective Janus kinase 1 and 2 inhibitor in patients with myelofibrosis. An update for clinicians

Published:2012-10-01 Issue:6 Volume:3 Page:341-354
ISSN:2040-6207
Container-title:Therapeutic Advances in Hematology
language:en
Short-container-title:Therapeutic Advances in Hematology

Author:

Harrison Claire¹,Vannucchi Alessandro M.²

Affiliation:

1. Guy’s and St Thomas’s NHS Foundation Trust, Guy’s Hospital, Great Maze Pond, London SE1 9RT, UK

2. Section of Hematology, Department of Critical Care, University of Florence, Florence, Italy

Abstract

Ruxolitinib became the first US Food and Drug Administration approved therapy for myelofibrosis in 2011 and EU approval is anticipated in summer 2012. Two large phase III trials (known as the COMFORT studies) were the basis for this approval and were published recently. In this review article we discuss the challenges in managing myelofibrosis, the information to date about ruxolitinib and speculate as to the future direction with this and similar agents.

Publisher

SAGE Publications

Subject

Hematology

Link

http://journals.sagepub.com/doi/pdf/10.1177/2040620712459746

Reference85 articles.

1. DNMT3A mutational analysis in primary myelofibrosis, chronic myelomonocytic leukemia and advanced phases of myeloproliferative neoplasms

2. Allogeneic hemopoietic SCT for patients with primary myelofibrosis: a predictive transplant score based on transfusion requirement, spleen size and donor type

3. Potent and Selective Inhibition of Polycythemia by the Quinoxaline JAK2 Inhibitor NVP-BSK805

4. Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference

5. Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the international working group for myelofibrosis research and treatment

Cited by 50 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Design, synthesis and evaluation of C-5 substituted pyrrolopyridine derivatives as potent Janus Kinase 1 inhibitors with excellent selectivity;European Journal of Medicinal Chemistry;2024-03

2. JAK/STAT defects and immune dysregulation, and guiding therapeutic choices;Immunological Reviews;2024-02-02

3. Ruxolitinib'in COVID-19 majör proteaz enzimine ve SARS CoV-2 spike glikoproteinine karşı inhibitör aktivitesi: Bir moleküler kenetlenme çalışması.;Open Journal of Nano;2023-12-21

4. Trans-vaccenic acid reprograms CD8+ T cells and anti-tumour immunity;Nature;2023-11-22

5. Discovery of C-5 Pyrazole-Substituted Pyrrolopyridine Derivatives as Potent and Selective Inhibitors for Janus Kinase 1;Journal of Medicinal Chemistry;2023-05-10